If these KMT inhibitors were combined with DNA-based treatments, such as IR or doxorubicin, which are commonly used in sarcomas, the impact on DNA damage could be significantly higher and thus lethal for the tumor cell. This evidence concerns the gene CAMKMT and sarcoma.